These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23090679)

  • 1. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
    Janes MR; Vu C; Mallya S; Shieh MP; Limon JJ; Li LS; Jessen KA; Martin MB; Ren P; Lilly MB; Sender LS; Liu Y; Rommel C; Fruman DA
    Leukemia; 2013 Mar; 27(3):586-94. PubMed ID: 23090679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
    Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
    Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
    Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Aug; 61(8):1486-9. PubMed ID: 24623675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
    Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
    Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
    Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
    Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
    Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
    Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
    Guo Y; Kwiatkowski DJ
    Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR
    Hsu PY; Wu VS; Kanaya N; Petrossian K; Hsu HK; Nguyen D; Schmolze D; Kai M; Liu CY; Lu H; Chu P; Vito CA; Kruper L; Mortimer J; Chen S
    Clin Cancer Res; 2018 Jan; 24(2):395-406. PubMed ID: 29079660
    [No Abstract]   [Full Text] [Related]  

  • 15. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.